mFOLFOX

mFOLFOX is a modified chemotherapy regimen consisting of oxaliplatin, leucovorin (folinic acid), and fluorouracil (5-FU). It is a standard-of-care treatment primarily used for colorectal cancer, particularly in the metastatic and adjuvant settings. The "modified" designation typically refers to variations in the administration schedule, such as the omission of the initial bolus of 5-FU or adjustments in the dosing of oxaliplatin and leucovorin to improve the safety profile while maintaining therapeutic efficacy. Oxaliplatin is a platinum-based antineoplastic agent that forms DNA cross-links, inhibiting DNA replication and transcription. Fluorouracil is a pyrimidine analog that acts as an antimetabolite, primarily by inhibiting thymidylate synthase to block DNA synthesis. Leucovorin is a reduced folate that is administered to stabilize the binding of fluorouracil to thymidylate synthase, thereby enhancing its cytotoxic effect.

Other names

modified FOLFOXfluorouracil + leucovorin + oxaliplatin